Year archive

Akeso, Inc. — 2021 filings

All 66 regulatory filings released by Akeso, Inc. (9926) in 2021, sourced directly from the official regulator.

66 Filings

2021 Period

2021 filings (66)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL OF GUMOKIMAB (IL-17A MONOCLONAL ANTIBODY, AK111) FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS Regulatory Filings	2021-12-28	English
VOLUNTARY ANNOUNCEMENT - EARLY COMPLETION OF PATIENT ENROLLMENT OF EBRONUCIMAB (PCSK9 MONOCLONAL ANTIBODY, AK102) IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMI Regulatory Filings	2021-12-21	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2021-12-21	English
CONTINUING CONNECTED TRANSACTIONS EXCLUSIVE SALES AGREEMENT OF PENPULIMAB MONOCLONAL ANTIBODY Regulatory Filings	2021-12-20	English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENT Regulatory Filings	2021-12-17	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2021-12-14	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2021-12-13	English
ADOPTION OF THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2021-12-07	English
VOLUNTARY ANNOUNCEMENT - LAUNCH OF INVESTIGATOR-INITIATED STUDY OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) IN THE UNITED STATES Regulatory Filings	2021-12-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2021 Regulatory Filings	2021-12-02	English
VOLUNTARY ANNOUNCEMENT - INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE Regulatory Filings	2021-11-04	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2021 Regulatory Filings	2021-11-02	English
VOLUNTARY ANNOUNCEMENT - PD-1/VEGF BI-SPECIFIC ANTIBODY (AK112) OBTAINED APPROVAL TO INITIATE A PHASE II CLINICAL TRIAL FOR MONOTHERAPY OR COMBINED CHEMOTHERAPY NEOADJUVANT/ADJUVANT THERAPY Regulatory Filings	2021-11-01	English
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT DOSED IN A CLINICAL TRIAL OF TIGIT MONOCLONAL ANTIBODY (AK127) IN COMBINATION WITH CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) FOR THE TREATM Regulatory Filings	2021-10-22	English
VOLUNTARY ANNOUNCEMENT - SIX LATEST RESEARCH RESULTS TO BE PUBLISHED AT THE SITC 2021 Regulatory Filings	2021-10-18	English
VOLUNTARY ANNOUNCEMENT - RAPID ADVANCEMENT OF PHASE II CLINICAL TRIAL OF IL-4R MONOCLONAL ANTIBODY (AK120) FOR THE TREATMENT OF ATOPIC DERMATITIS AND ASTHMA Regulatory Filings	2021-10-12	English
VOLUNTARY ANNOUNCEMENT - PD-1/VEGF BI-SPECIFIC ANTIBODY(AK112) OBTAINED APPROVAL TO INITIATE CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED MALIGNANT TUMORS Regulatory Filings	2021-10-11	English
VOLUNTARY ANNOUNCEMENT - PD-1/VEGF BI-SPECIFIC ANTIBODY(AK112) OBTAINED APPROVAL TO INITIATE CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED TRIPLE-NEGATIVE BREAST CANCER Regulatory Filings	2021-10-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2021 Regulatory Filings	2021-10-04	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT FOR PHASE II CLINICAL TRIAL OF IL-17A MONOCLONAL ANTIBODY (AK111) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Regulatory Filings	2021-09-29	English
VOLUNTARY ANNOUNCEMENT - IL-4R MONOCLONAL ANTIBODY (AK120) OBTAINED APPROVAL TO INITIATE A GLOBAL PHASE II CLINICAL TRIAL FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS Regulatory Filings	2021-09-27	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) FOR THE TREATMENT OF RELAPSED OR METASTATIC CERVICAL CANCER ACCEPTED BY NMPA Regulatory Filings	2021-09-24	English
2021 INTERIM REPORT Regulatory Filings	2021-09-23	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2021 Regulatory Filings	2021-09-06	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021 Regulatory Filings	2021-08-31	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) FOR RELAPSED OR METASTATIC CERVICAL CANCER OBTAINED APPROVAL FROM THE CDE TO SUBMIT NEW DRUG APPLICATION AND WAS GRANTED PR Regulatory Filings	2021-08-23	English
DATE OF BOARD MEETING Regulatory Filings	2021-08-19	English
VOLUNTARY ANNOUNCEMENT - LATEST UPDATES ON THE CLINICAL TRIALS OF AK104 AND AK105 WILL BE PUBLISHED AT ESMO 2021 Regulatory Filings	2021-08-09	English
INSIDE INFORMATION ANNOUNCEMENT - PENPULIMAB MONOCLONAL ANTIBODY (PD-1) OBTAINED MARKETING APPROVAL IN CHINA Regulatory Filings	2021-08-05	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR PENPULIMAB MONOCLONAL ANTIBODY (PD-1) FOR THIRD-LINE TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA ACCEPTED BY NMPA Regulatory Filings	2021-08-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2021 Regulatory Filings	2021-08-04	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) IN COMBINATION WITH VEGFR-2 MONOCLONAL ANTIBODY OBTAINED APPROVAL TO INITIATE PHASE Ib/II CLINICAL TRIAL FOR TREATMENT Regulatory Filings	2021-08-04	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) INITIATED PHASE III CLINICAL TRIAL FOR FIRST-LINE TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA OR GASTROESOPHAGEAL JUNCTION Regulatory Filings	2021-08-03	English
VOLUNTARY ANNOUNCEMENT - CD47 MONOCLONAL ANTIBODY (AK117) COMPLETED PHASE I DOSE ESCALATION TRIAL AND OBTAINED APPROVAL TO INITIATE CLINICAL TRIAL IN COMBINATION WITH AZACITIDINE FOR TREATMENT OF ACUT Regulatory Filings	2021-07-13	English
VOLUNTARY ANNOUNCEMENT - COMPLETED PATIENT ENROLLMENT OF THE FIRST COHORT WITH CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) IN COMBINATION WITH CD47 MONOCLONAL ANTIBODY (AK117) FOR TREATMENT OF Regulatory Filings	2021-07-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2021 Regulatory Filings	2021-07-05	English
VOLUNTARY ANNOUNCEMENT CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) IN COMBINATION WITH VEGFR-2 MONOCLONAL ANTIBODY OBTAINED APPROVAL TO INITIATE PHASE Ib/II CLINICAL TRIAL FOR TREATMENT O Regulatory Filings	2021-07-05	English
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR PENPULIMAB MONOCLONAL ANTIBODY (PD-1) FOR FIRST-LINE TREATMENT OF SQUAMOUS NON-SMALL-CELL LUNG CANCER ACCEPTED BY NMPA Regulatory Filings	2021-07-02	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MONDAY, JUNE 28, 2021 Regulatory Filings	2021-06-28	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2021 Regulatory Filings	2021-06-02	English
VOLUNTARY ANNOUNCEMENT - PENPULIMAB MONOCLONAL ANTIBODY (PD-1) IS SELECTED UNDER THE NEW POLICY OF REAL-TIME ONCOLOGY REVIEW (RTOR) OF THE FDA AND BLA ALREADY SUBMITTED IN THE UNITED STATES FOR TREATM Regulatory Filings	2021-05-24	English
VOLUNTARY ANNOUNCEMENT - LATEST UPDATES ON THE CLINICAL TRIALS OF AK104, AK112, AK117 AND AK105 PUBLISHED AT ASCO 2021 Regulatory Filings	2021-05-20	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR PHASE I/II CLINICAL TRIAL OF CD47 MONOCLONAL ANTIBODY (AK117) FOR TREATMENT OF MEDIUM- TO HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) Regulatory Filings	2021-05-18	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 28, 2021 Regulatory Filings	2021-05-13	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2021-05-13	English
NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2021-05-13	English
VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE MSCI CHINA INDEX Regulatory Filings	2021-05-13	English
VOLUNTARY ANNOUNCEMENT - INITIATION OF VARIOUS CLINICAL TRIALS OF PD-1/VEGF BI-SPECIFIC ANTIBODY (AK112) Regulatory Filings	2021-05-12	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2021 Regulatory Filings	2021-05-06	English
2020 ANNAUL REPORT Regulatory Filings	2021-04-29	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) OBTAINED APPROVAL TO INITIATE GLOBAL PHASE III CLINICAL TRIAL FOR FIRST-LINE TREATMENT OF ADVANCED CERVICAL CANCER Regulatory Filings	2021-04-28	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2021 Regulatory Filings	2021-04-07	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 Regulatory Filings	2021-03-31	English
VOLUNTARY ANNOUNCEMENT - PENPULIMAB (PD-1) OBTAINED BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR THIRD-LINE TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA Regulatory Filings	2021-03-30	English
DATE OF BOARD MEETING Regulatory Filings	2021-03-18	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2021 Regulatory Filings	2021-03-03	English
VOLUNTARY ANNOUNCEMENT - INTERIM ANALYSIS OF THE PHASE III CLINICAL TRIAL OF PENPULIMAB MONOCLONAL ANTIBODY (PD-1) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE SQUAMOUS NON-SMALL CELL LUNG CANCER H Regulatory Filings	2021-02-23	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) OBTAINED ORPHAN DRUG DESIGNATION FROM FDA OF THE UNITED STATES FOR TREATING CERVICAL CANCER Regulatory Filings	2021-02-22	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2021 Regulatory Filings	2021-02-02	English
VOLUNTARY ANNOUNCEMENT - SUCCESSFUL DOSING OF THE FIRST PATIENT WITH CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) IN COMBINATION WITH CD73 MONOCLONAL ANTIBODY (AK119) FOR TREATMENT OF ADVANCED Regulatory Filings	2021-01-28	English
VOLUNTARY ANNOUNCEMENT - LATEST STUDY OF PENPULIMAB MONOCLONAL ANTIBODY (PD-1) IN COMBINATION WITH ANLOTINIB FOR 1L ADVANCED HCC PUBLISHED AT THE 2021 ASCO GI Regulatory Filings	2021-01-19	English
VOLUNTARY ANNOUNCEMENT - LATEST RESULTS OF PHASE IB/II STUDY OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) FOR THE FIRST-LINE TREATMENT OF ADVANCED GASTRIC CANCER OR ADENOCARCINOMA OF G Regulatory Filings	2021-01-19	English
Next Day Disclosure Return Regulatory Filings	2021-01-14	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2021-01-14	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2021-01-07	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2020 Regulatory Filings	2021-01-06	English